Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.
Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
9hon MSN
When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results